Table 2.
Comparison of clinical course between non-survivors and survivors among patients with SJS-ILD.
| Characteristics | Total | Non-survivors | Survivors | P value |
|---|---|---|---|---|
| Patient number | 24 | 26 | 12 | |
| Acute exacerbation | 7 (11.3) | 3 (20) | 4 (8.5) | 0.345 |
| Pneumonia | 9 (14.5) | 5 (33.3) | 4 (8.5) | 0.031 |
| Pulmonary hypertension | 4 (6.5) | 3 (20) | 1 (2.1) | 0.041 |
| ILD progression | 27 (43.5) | 10 (66.7) | 17 (36.2) | 0.038 |
| Lung function decline ratea | ||||
| FVC change, %predicted/year | − 1.18 ± 2.04 | − 2.77 ± 2.20 | − 0.59 ± 1.70 | < 0.001 |
| DLCO change, %predicted/year | − 1.45 ± 1.68 | − 2.65 ± 1.92 | − 1.07 ± 1.41 | 0.001 |
| TLC change, %predicted /year | 0.11 ± 1.91 | − 0.45 ± 2.03 | 0.29 ± 1.86 | 0.197 |
Data are presented as mean ± standard deviation or number (%), unless otherwise indicated.
DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, ILD interstitial lung disease, SJS Sjögren syndrome, TLC total lung capacity.
aLung function decline rate was defined as the slope of linear function estimated using a linear mixed-effects model with random intercept and random slope.